News & Updates

Obesity does not seem to have any significant impact on clinical outcomes, particularly survival, in patients with multiple myeloma (MM), according to a study presented at EHA 2023. However, obese MM patients aged <65 years tend to have a shorter overall survival (OS) than those with normal weight.

In patients with focal epilepsy, seizure frequency at baseline and the number of previous antiseizure medications (ASMs) used can predict sustained reduction in seizure frequency with adjunctive brivaracetam, according to data from the BRIVAFIRST study.

Certain comorbidities such as hypertension and diabetes mellitus (DM), along with locally advanced stage at diagnosis and systemic treatment received (ie, doxorubicin), are significantly associated with tumour recurrences among patients with breast cancer, according to a study presented at the recent ASCO Breakthrough 2023.

A trend towards a favourable overall (OS) and disease-free survival (DFS) at 21 months follow-up has been observed among patients with early breast cancer enrolled to a government program that grants medicines access to indigent individuals, reports a study presented at ASCO Breakthrough 2023.

Patients with chronic myeloid leukaemia (CML) who are being treated with both tyrosine kinase inhibitors (TKIs) and selective serotonin reuptake inhibitors (SSRIs) do not appear to be at greater total risk of bleeding or thrombotic events than those on TKIs only, reveals a study. However, concomitant use of TKIs and SSRIs may elevate the risk of intracranial bleeding.

Asians of different ethnicities have different risk factors for type 2 diabetes (T2D), according to a study, highlighting the potential value of tailored prevention and treatment strategies.